Although chemotherapy remains one of the main types of treatment for cancer, treatment failure is a frequent occurrence, emphasizing the need for new approaches to the early assessment of tumor response. The aim of this study was to search for indicators based on optical imaging of cellular metabolism and of collagen in tumors in vivo that enable evaluation of their response to chemotherapy. The study was performed on a mouse colorectal cancer model with the use of cisplatin, paclitaxel, and irinotecan. The metabolic activity of the tumor cells was assessed using fluorescence lifetime imaging of the metabolic cofactor reduced nicotinamide adenine dinucleotide (phosphate), NAD(P)H. Second harmonic generation (SHG) imaging was used to analyze the extent and properties of collagen within the tumors. We detected an early decrease in the free/bound NAD(P)H ratio in all treated tumors, indicating a shift toward a more oxidative metabolism. Monitoring of collagen showed an early increase in the amount of collagen followed by an increase in the extent of its orientation in tumors treated with cisplatin and paclitaxel, and decrease in collagen content in the case of irinotecan. Our study suggests that changes in cellular metabolism and fibrotic stroma organization precede morphological alterations and tumor size reduction, and that this indicates that NAD(P)H and collagen can be considered as intrinsic indicators of the response to treatment. This is the first time that these parameters have been investigated in tumors in vivo in the course of chemotherapy with drugs having different mechanisms of action.COLORECTAL cancer is one of the most common cancers in the world. The current standard treatments for colorectal cancer include surgery, radiation therapy, and chemotherapy. Treatment options and recommendations depend on several factors, such as the type and stage of the cancer, possible side effects, and the patient's preferences and overall health.In standard clinical practice neoadjuvant chemotherapy is used for patients with stage II and III Ńolorectal cancer to facilitate resection of those tumors that were once considered unresectable. Adjuvant chemotherapy is recommended for Stage III colorectal cancer after resection to prevent tumor recurrence and the development of metastases (1). When resection of all known tumor sites is no longer possible or advisable, palliative care is offered. Current guidelines on the chemotherapy of Ńolorectal cancer prescribe the use of platinum drugs (oxaliplatin, cisplatin, or similar), or irinotecan in various combinations with a fluoropyrimidine (capecitabine or 5-fluorouracil). Additionally, paclitaxel can be used for chemotherapy of colorectal cancer in combination with 5-fluorouracil.